Pharmacovigilance and drug safety software helps companies collect, process, assess and report adverse events for medicines, vaccines and medical devices. It ranges from safety databases and case intake to adverse event reporting, literature monitoring and signal detection, including electronic reporting to health authorities in the ICH E2B format. Life Sciences Digital tracks 66 tools from 32 companies in this category.
Function
Tool type
Compliance
Unified safety data intake from multiple channels with MedDRA coding, duplicate detection, and expert-in-the-loop workflows for pharmacovigilance.
AI-native safety database that shifts pharmacovigilance from passive data storage to active, real-time intelligence with transparent, explainable reasoning.
Advanced Signals by ArisGlobal
Signal and risk management with GenAI-powered detection, case evaluation, and automated workflows for pharmacovigilance.
Adverse Event Database by DrugCard
Centralized adverse event data collection, storage, and E2B(R2/R3) reporting with AI-powered signal detection and full regulatory compliance.
adWATCH - AE by Atlant Systems
Adverse event reporting and management for clinical trials, generating FDA MedWatch and CIOMS reports.
AE Connect by QORO Intelligence
AI-powered adverse event intake and triage that captures reports through guided forms and sends structured, coded cases directly into Veeva, Argus, or your safety database.
Post-marketing vaccine safety surveillance with adverse event reporting, management, and automatic MedDRA coding. 21 CFR 11 compliant.
AI-Powered Literature Monitoring by DrugCard
Automated medical literature monitoring and safety signal detection across 121+ countries and 2200+ local sources for pharmacovigilance teams.
Aushadhi by Inductive Quotient
AI-assisted medical coding for clinical trials and pharmacovigilance, generating high-confidence MedDRA and WHO Drug suggestions with governed review workflows.
Biologit MLM-AI Platform by Biologit
AI-driven literature monitoring and signal detection for pharmacovigilance with global and local surveillance, audit-ready compliance, and automated workflows.
A tool belongs here when its main job is to detect, process, assess or report safety information. Typical functions include:
AI Regulatory & Medical Writing covers dedicated tools for writing periodic safety reports such as PSURs, PBRERs and DSURs.
Managing the cases and data behind those reports belongs here.
Regulatory Submission Automation covers marketing application dossiers.
Electronic reporting of individual cases stays here.
Computational Drug Safety & PKPD Modeling covers predicting toxicity and safety before a product reaches patients.
Regulatory intelligence tools that monitor changing pharmacovigilance rules sit in Regulatory Information Management.
47 of the 66 tools automate defined workflow steps and 12 are analytical platforms; none works as a copilot. AI is built into the workflow instead: vendors describe AI or machine learning in 34 tools, 52 percent of the category, against 41 percent across the full Life Sciences Digital database.
28 tools handle case intake, triage and coding, and 23 signal detection and safety analytics. 16 cover adverse event reporting and distribution, 12 literature monitoring and 11 safety databases and case management. Smaller groups cover compliance and risk management (9), clinical trial safety (7) and device and vaccine vigilance (4).
All 11 safety databases and 10 of the 12 literature monitoring tools are described as AI-powered. In clinical trial safety the figure is 2 of 7, and in device and vaccine vigilance 1 of 4.
Four companies account for 30 of the 66 tools, typically as modular suites: Nextrove (10), ArisGlobal (8), Clinevo Technologies (6) and RxLogix (6). At the same time, 21 companies offer a single specialised tool. Across the category, 22 tools cover more than one function.
24 tools address medical device companies, more than the other two Regulatory & Safety Documentation categories combined (4). Most are general safety systems that also serve device makers; 4 tools focus specifically on device and vaccine vigilance.
24of 66 tools address medical device companies
Vendors cite ICH alignment for 57 tools, GxP for 55 and 21 CFR Part 11 for 38. These are vendor statements; buyers should verify them during evaluation.
The category includes VigiFlow and VigiLyze from the Uppsala Monitoring Centre, the organisation behind VigiBase, the WHO global database of reported adverse events. Both are built for national safety databases.
Data: Life Sciences Digital database, snapshot of 28 October 2026. Classification follows the methodology below.
Confirm full E2B(R3) support and tested connections to the reporting channels you use, such as FDA’s ESG NextGen and EudraVigilance.
Check MedDRA and WHODrug coding support, duplicate detection and data validation at intake.
Look at which sources the tool accepts directly: call centres, patient programmes, partners, literature, social media and clinical trials.
For literature monitoring, ask which global and local sources are screened and how relevant articles are flagged and documented.
Understand which statistical methods and data sources are used, and how signals are tracked through evaluation.
Safety data exchange agreements, reconciliation with partners and submission compliance tracking matter as soon as more than one company handles the same product.
Where AI processes cases or literature, ask how outputs are validated, monitored over time and reviewed by people.
Moving from one safety database to another is a major project. Ask about migration support, validation packages and performance at your case volume.
Core systems that store individual case safety reports and manage them from receipt to submission.
Tools that capture adverse event reports from multiple channels, structure them, code them with MedDRA and WHODrug and route them for assessment.
Tools that screen scientific and local literature for adverse events and potential cases.
Tools that analyse safety data, often alongside real-world data, to detect, evaluate and track potential safety signals.
Tools that apply reporting rules, generate E2B messages, transmit cases to authorities and distribute safety information to partners and sites.
Tools that monitor submission timeliness, manage safety data exchange agreements, track quality issues and support risk management plans.
Tools that manage serious adverse events and safety reporting during clinical trials.
Tools for device incident reporting, post-market surveillance and adverse events following immunisation.
FDA’s Adverse Event Monitoring System (AEMS), formerly FAERS, has required E2B(R3) for premarketing IND safety reports from commercial sponsors submitted via ESG NextGen since 1 April 2026. Since 1 October 2026, all ICSRs submitted via ESG NextGen must use E2B(R3); FDA accepted E2B(R2) only through 30 September 2026.
The Council for International Organizations of Medical Sciences (CIOMS) published the report of its Working Group XIV on artificial intelligence in pharmacovigilance on 4 December 2025. It gives companies and regulators common terminology and principles for using AI in safety work, including risk-based use, human oversight and ongoing validation of AI tools. In January 2026, FDA and EMA added ten joint guiding principles for good AI practice in drug development, built on the same risk-based, lifecycle approach.
Software that helps companies collect, process, assess and report adverse events and safety signals for their products, in line with pharmacovigilance regulations and ICH standards.
Case processing is the handling of an individual case safety report (ICSR) from receipt to submission: intake, data entry, medical coding with MedDRA and WHODrug, assessment of seriousness, expectedness and causality, quality review and electronic reporting to health authorities within regulatory timelines.
The core system where a company stores and manages individual case safety reports for its products. It supports case processing, coding, electronic reporting in the E2B format and the data analysis behind signal detection and periodic safety reports. Examples in our database include Oracle Safety One Argus, ArisGlobal MultiVigilance and Veeva Safety.
There is no single best system. The right choice depends on your case volume, whether you need a full safety database or a specialised tool for intake, literature monitoring or signal detection, the systems you already use and the authorities you report to. The evaluation criteria on this page help narrow the list.
E2B(R3) support and gateway connections, MedDRA and WHODrug coding, supported intake channels, literature coverage, signal detection methods, partner and compliance management, oversight of any AI features and support for data migration.
The ICH standard for the electronic transmission of individual case safety reports between companies and regulators. In the US, FDA has required E2B(R3) for all ICSRs submitted via ESG NextGen since 1 October 2026.
Yes. Vendors describe AI for case intake and data extraction, medical coding, duplicate detection, literature screening, narrative generation and signal detection; 34 of the 66 tools in this category are AI-powered. Safety teams remain accountable for the outcome, and the CIOMS Working Group XIV report sets out principles for validation and human oversight of such tools.
Most systems follow ICH E2B for safety reporting and offer audit trails, access controls and electronic signatures. In our database, vendors cite ICH alignment for 57 of the 66 tools, GxP for 55 and Part 11 for 38. Ask for validation documentation during evaluation.
Pharmacovigilance software manages safety data and its reporting. Regulatory writing tools create document content, and submission tools package and publish marketing application dossiers.
Yes. In our database, 60 of the 66 pharmacovigilance tools are offered as cloud software, with hybrid or on-premise options from a few vendors. Data residency, validation and access control are the main points to confirm.
Tools are included when their main purpose is to detect, process, assess or report safety information, following the definition above. Life Sciences Digital classifies each tool based on the vendor’s own product information. AI capabilities and compliance reflect what vendors state publicly; we do not test or certify products. Statistics on this page are calculated from our database as of 28 October 2026. Vendors can submit or correct a listing through our tool onboarding form.
Last reviewed:
AI tools that draft and check the content of regulatory and clinical documents, such as clinical study reports, protocols, safety reports and health authority responses.
Software that compiles, validates, publishes and tracks eCTD submissions and other regulatory dossiers.
